The abstract is read at the publisher; the summary is JClub's.
VT104 TEAD palmitoylation inhibition is brain-penetrant in patient-derived orthotopic xenograft glioblastoma models, achieving a brain:plasma ratio >150% at therapeutic dosing without systemic toxicity.
- Why it matters: YAP-TEAD signaling supports adaptive plasticity, invasion, and resistance during glioblastoma recurrence, creating a need for adjuvant strategies that can be paired with standard chemoradiation.
- What they did: Across patient-derived GBM cell lines, VT103/VT104 were tested for effects on proliferation, migration, and TEAD activity, then VT104 pharmacokinetics and brain biodistribution were measured by mass spectrometry in PDX mice.
- The result: In two genetically distinct recurrent GBM PDX models, VT104 plus radiotherapy and temozolomide significantly extended overall survival, with the strongest benefit in EGFR-mutant tumors and reduced overall and infiltrative burden.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.